Business Wire

Gilead Sciences Completes Acquisition of Kite Pharma, Inc.

Del

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead (“Purchaser”), to acquire Kite Pharma, Inc. (Nasdaq: KITE) for $180 per share, net to the seller in cash, without interest, or approximately $11.9 billion in the aggregate.

On August 28, 2017, Gilead and Kite announced that Kite, Gilead and Purchaser had signed a definitive merger agreement pursuant to which a tender offer would be made. Pursuant to the merger agreement, Gilead and Purchaser commenced a tender offer on September 5, 2017 to acquire all outstanding shares of Kite at a price of $180 per share, net to the seller in cash, without interest. On October 3, 2017, Gilead announced that it had successfully completed the tender offer for all outstanding shares of common stock of Kite and had accepted for payment all shares validly tendered and not withdrawn as of the expiration time of the tender offer and would promptly pay for such shares, which shares represented approximately 66.20% of Kite’s outstanding shares (including 2,003,002 shares delivered through Notices of Guaranteed Delivery, representing approximately 3.46% of the shares outstanding). Pursuant to the terms of the merger agreement, Purchaser merged with and into Kite on October 3, 2017. All outstanding shares of common stock of Kite, other than (i) shares owned by Gilead, Purchaser or any of their direct or indirect wholly-owned subsidiaries, (ii) shares owned by Kite (or held in Kite’s treasury) and (iii) shares held by Kite stockholders who properly demand appraisal for their shares under Delaware law, were canceled and converted into the right to receive cash equal to the $180 price per share.

As a result of the completion of the merger, Kite has become a wholly-owned subsidiary of Gilead and the common stock of Kite will no longer be listed for trading on the NASDAQ Global Select Market, which is expected to take effect as of the close of market on October 3, 2017.

“We are excited to welcome more than 700 talented Kite employees to the Gilead organization,” said John F. Milligan, PhD, Gilead’s President and Chief Executive Officer. “Throughout our respective histories, each company has demonstrated a deep commitment to advancing life-saving therapies for people who need them. I look forward to all that we will accomplish together, as a combined organization.”

Bank of America Merrill Lynch, Lazard and Barclays acted as financial advisors to Gilead. Skadden, Arps, Slate, Meagher & Flom LLP acted as Gilead’s legal advisors.

Centerview Partners acted as exclusive financial advisor to Kite. Jeffries LLC and Cowen and Company, LLC also provided advice to Kite. Sullivan & Cromwell LLP and Cooley LLP acted as Kite’s legal advisors.

About Kite

Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system’s ability to recognize and kill tumors. On March 31, 2017, Kite submitted a Biologics License Application to the FDA for its lead product candidate, axi-cel, as a treatment for patients with relapsed or refractory aggressive non-Hodgkin lymphoma who are ineligible for autologous stem cell transplant. Kite received priority review on May 29, 2017 with the Prescription Drug User Fee Act action date set for November 29, 2017. In July 2017, Kite announced the submission of a Marketing Authorization Application to the European Medicines Agency for axi-cel as a treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) who are ineligible for autologous stem cell transplant. These submissions come after positive results from Kite’s ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma. Kite is based in Santa Monica, California. For more information on Kite, please visit www.kitepharma.com.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Gilead’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of Gilead and members of its senior management team. Forward-looking statements include, without limitation, statements regarding the business combination, its effect on Gilead’s revenues and earnings, the commercial success of Kite’s products, approval of axi-cel by regulatory authorities, the ability of Gilead to advance Kite’s product pipeline, including axi-cel, the anticipated timing of clinical data; the possibility of unfavorable results from clinical trials; difficulties or unanticipated expenses in connection with integrating the companies; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: the effects of the transaction on relationships with employees, customers, other business partners or governmental entities; other business effects, including the effects of industry, economic or political conditions outside of the companies’ control; transaction costs; actual or contingent liabilities; and other risks and uncertainties detailed from time to time in the Gilead’s periodic reports filed with the Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000

Contact information

Gilead Sciences, Inc.
Investors
Sung Lee, 650-524-7792
or
Media
Amy Flood, 650-522-5643

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Robinson Fresh® and Verfrut Bring Premium Fruit to Europe21.2.2018 04:00Pressemelding

Robinson Fresh®, a division of C.H. Robinson, is now the primary provider of Verfrut products in Europe. Verfrut is one of the largest fruit growers in South America with items such as grapes, apples, stone fruit, cherries, pears, kiwifruit, clementines and organic bananas. With this strategic alliance, the companies bring together expertise in cold chain logistics and produce to provide a more integrated fruit offering to Europeans. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180220006476/en/ “When we heard Verfrut was looking for opportunities to expand into the European market, we knew we could work together to bring these premium products to our customers,” Robert Walsleben, European director for Robinson Fresh, said. “Verfrut is one of the largest fruit growers out of Chile and Peru. They are also family owned, feature significant production and care about providing flavorful products to their customers. Europeans wil

Bigelow Space Operations Announces Partnership with CASIS to Fly Payloads to the International Space Station21.2.2018 00:18Pressemelding

Bigelow Space Operations (BSO) is proud to announce a partnership with the Center for the Advancement of Science in Space (CASIS), manager of the International Space Station (ISS) U.S. National Laboratory. BSO is officially a user of the ISS National Lab, and will be facilitating the integration of payloads for commercial, academic and government customers. In this capacity, BSO intends to contract with other payload integrating companies where we not only can help those companies to develop their dynamic futures for themselves and their successful clients extending beyond ISS operations, but to also offer ourselves as a customer and understand how to help CASIS. This may be important if CASIS is to someday enable usage of B330 stations. BSO’s mandate is to promote the services of the ISS National Lab, promote other payload facilitating companies and to develop new relationships for the ISS and Bigelow Aerospace stations. BSO will kick off this through a recently awarded CASIS partner

Bigelow Aerospace Announces the Creation of Bigelow Space Operations20.2.2018 22:00Pressemelding

Bigelow Aerospace is excited to introduce Bigelow Space Operations (BSO), a new commercial space company that is the sales, operational and customer service company that manages and operates space stations developed by Bigelow Aerospace. With the two launches of B330-1 and B330-2 expected in 2021, the time is now in 2018 to begin BSO activity. These single structures that house humans on a permanent basis will be the largest, most complex structures ever known as stations for human use in space. The customers that B330 will seek to accommodate will be very diverse. Bigelow Space Operations has a mission to market and operate these and other space stations including future generations developed by Bigelow Aerospace that are so capable, so diverse and so large that they can accommodate virtually unlimited use almost anywhere. Over time, Bigelow Aerospace will manufacture a single station, launched on a single rocket that will contain over 2.4 times the pressurized volume of the entire In

Andersen Tax & Legal Launches in Egypt20.2.2018 14:30Pressemelding

The Andersen name launches in Egypt this week as Maher Milad Iskander and Co., an Egyptian tax and legal firm based in Cairo, formally adopts the name Andersen Tax & Legal. Maher Milad Iskander and Co. became a collaborating firm of Andersen Global in July of 2017 and is one of three that have become member firms and adopted the Andersen name thus far in 2018. Maher Milad Iskander, Managing Partner of Andersen Tax & Legal in Egypt, said, “Andersen Global’s strategy of focusing on outstanding tax and legal services will provide us with many advantages and will allow us to even better serve our cross-border clientele. We are looking forward to our continued work with the Andersen team and to seamlessly providing innovative and client-focused solutions on a global level through our colleagues around the world.” “Egypt is considered to be one of the highest growing markets in the world and our adoption of the Andersen name in Egypt has come at the perfect time,” added Global Chairman and A

Proposals of the Supervisory Board to Be Submitted to the Annual General Shareholders' Meeting of Sartorius AG20.2.2018 14:00Pressemelding

At today’s meeting, the Supervisory Board of Sartorius AG, approved the Executive Board’s recommendation to submit a proposal to the Annual General Shareholders’ Meeting on April 5, 2018, to raise dividends to 0.51 euros per preference share and 0.50 euros per ordinary share. Prior-year dividends were 0.46 euros and 0.45 euros per preference share and per ordinary share, respectively. Therefore, the total amount disbursed under this proposal would increase by 11.0% to 34.5 million euros from 31.1 million euros a year earlier. In addition, the Supervisory Board will submit a proposal to the Annual General Shareholders’ Meeting to elect Dr. Guido Oelkers to the Supervisory Board as a representative of the shareholders. Guido Oelkers has already been a member of this board since November 2017. He was appointed by court order after Supervisory Board member Professor Arnold Picot, Ph.D., had passed away. Guido Oelkers, who was born in 1965 and holds a university degree in business administr

ETECSA Enhances Connectivity to the Rest of the World with SES Networks20.2.2018 14:00Pressemelding

Cubans and visitors to Cuba will have additional access to reliable and uninterrupted connectivity throughout the main island of Cuba as ETECSA, Cuba’s national telecommunications operator, signed a deal with SES Networks for satellite services, SES announced today. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180220005894/en/ ETECSA Enhances Connectivity to the Rest of the World with SES Networks (Photo: Business Wire) SES Networks will augment ETECSA’s existing terrestrial infrastructure with its high-performance fibre-like medium earth orbit (MEO) capacity and improve connectivity for end-customers of the Cuban operator. “By working with SES Networks, we are ensuring that our customers across the main island will have a new way to access high-performing Internet at all times through this innovative satellite system. Our collaboration with SES Networks highlights ETECSA’s mission of providing telecommunications services t